Received Jun 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 2 | — | — |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 3 | — | — |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | — | — |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | — | — |
No symptoms reported at the time of the call; extradose adminsitered; This spontaneous report was received from a health care professional on 23-Jun-2025 and refers to a 5-year-old male patient. The patient's medical history, and concurrent conditions were not reported. Historical vaccines included Measles, mumps, and rubella virus vaccine live (M-M-R II), and (Varicella zoster vaccine live (Oka/Merck)) (VARIVAX), administered on 15-Jun-2021. Concomitant therapies were not reported. On 02-Oct-2024, the patient was vaccinated with a second dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD)injection, dose: 0.5 mL (route of administration, anatomical location, lot # and expiration date were not reported) with sterile diluent, dose: 0.5 mL (route of administration, anatomical location, lot # and expiration date were not reported), on the same date for prophylaxis. On 29-May-2025, the patient was vaccinated with a third dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) injection,dose: 0.5 mL (route of administration, anatomical location, lot # and expiration date were not reported) with sterile diluent, dose: 0.5 mL (route of administration, anatomical location, lot # and expiration date were not reported), on the same date for prophylaxis (Extra dose administered). No symptoms reported at the time of the call.